‘Laughter Therapy’ Is Shown To Reduce Heart Disease Risk In Brazilian Study: ‘Exciting To See’

Laughter has been called “the best medicine” for many decades — and now there’s scientific proof. A study from the Hospital de Clínicas de Porto Alegre in Brazil has shown that regular chuckling expands heart tissue and promotes the flow of oxygen in the body, thus reducing the risk of cardiac disease. “Laughter therapy” was also ...

Read More

AHA: Biden Admin’s Short-Term Plan Crackdown A Good Start On Addressing ‘Convoluted’ Coverage Gaps

Hospitals are on board with the Biden administration’s increased scrutiny of “inadequate” short-term health plans, and are hoping that the federal government will go further in its crackdown on payers’ “convoluted policies.” In early July, the White House said it was working to reverse a controversial Trump-era rule that expanded the duration of the controversial ...

Read More

ACA’s 2024 Affordability Percentage Drops To 8.39%

This is a relatively significant drop from the 2023 affordability percentage, which is 9.12%. The ACA affordability ratio applies to Applicable Large Employers (ALEs), which are subject to the ACA’s employer mandate. ALEs must use the ratio to determine affordability of the health plans offered to eligible full-time employees, in accordance with ACA law.

Read More

Slightly Higher Times: Biden Administration Moves To Loosen Weed Restrictions

The Biden administration’s Department of Health and Human Services is recommending that the Drug Enforcement Administration significantly loosen federal restrictions on marijuana but stopped short of advising that it should be entirely removed from the Controlled Substances Act.

Read More

California Pharmacies Are Making Millions Of Mistakes. They’re Fighting To Keep That Secret

California pharmacies, including those owned by big chains, make an estimated 5 million errors a year — but they’re not required to report them to state regulators.

Read More

Pharmaceutical Industry Rips ‘Draconian’ Price Negotiation Provision

The Biden administration and federal regulators may be taking a victory lap following the unveiling of the Centers for Medicare & Medicaid Services’ (CMS’) price negotiations list, but major players in the pharmaceutical industry feel the White House overstepped and think innovation will be stifled, ultimately leading to the creation of fewer life-changing drugs. Tuesday, CMS ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square